These data collectively suggest a chronic inflammatory condition caused by DSS-induced intestinal barrier dysfunction reduces hepatic SIRT1 expression and consequently suppresses SIRT1-mediated metabolic processes, which at least in part contributes to the development of hepatic steatosis and hypo-HDL cholesterolemia. This evidence concerns the gene SIRT1 and fatty liver disease.